Prediction of Long-Term Outcomes in ST-Elevation Myocardial Infarction and Non-ST Elevation Myocardial Infarction with and without Creatinine Kinase Elevation—Post-Hoc Analysis of the J-MINUET Study
Abstract
:1. Introduction
2. Methods
2.1. Study Overview and Design
2.2. Statistical Analysis
3. Results
3.1. STEMI
3.2. NSTEMI+CK
3.3. NSTEMI-CK
4. Discussion
4.1. Study Limitations
4.2. Clinical Implications/Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Antman, E.; Bassand, J.-P.; Klein, W.; Ohman, M.; Sendon, J.L.L.; Rydén, L.; Simoons, M.; Tendera, M. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined—A consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. J. Am. Coll. Cardiol. 2000, 36, 959–969. [Google Scholar] [CrossRef] [Green Version]
- Ogawa, H.; Kojima, S. Modern state of acute myocardial infarction in the interventional era: Observational case-control study—Japanese acute coronary syndrome study (JACSS). J. Cardiol. 2009, 54, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Daida, H.; Miyauchi, K.; Ogawa, H.; Yokoi, H.; Matsumoto, M.; Kitakaze, M.; Kimura, T.; Matsubara, T.; Ikari, Y.; Kimura, K.; et al. PACIFIC investigators. Management and two-year long-term clinical outcome of acute coronary syndrome in Japan: Prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry. Circ. J. 2013, 77, 934–943. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ishihara, M.; Fujino, M.; Ogawa, H.; Yasuda, S.; Noguchi, T.; Nakao, K.; Ozaki, Y.; Kimura, K.; Suwa, S.; Fujimoto, K.; et al. J-MINUET investigators. Clinical presentation, management and outcome of Japanese patients with acute myocardial infarction in the troponin era -Japanese Registry of Acute Myocardial Infarction Diagnosed by Universal Definition (J-MINUET). Circ. J. 2015, 79, 1255–1262. [Google Scholar] [CrossRef] [Green Version]
- Ishihara, M.; Nakao, K.; Ozaki, Y.; Kimura, K.; Ako, J.; Noguchi, T.; Fujino, M.; Yasuda, S.; Suwa, S.; Fujimoto, K.; et al. J-MINUET Investigators. Long-Term Outcomes of Non-ST-Elevation Myocardial Infarction Without Creatine Kinase Elevation—The J-MINUET Study. Circ. J. 2017, 81, 958–965. [Google Scholar] [CrossRef] [Green Version]
- Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Simoons, M.L.; Chaitman, B.R.; White, H.D. The Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third Universal Definition of Myocardial Infarction. Circulation 2012, 126, 2020–2035. [Google Scholar] [CrossRef] [Green Version]
- Mehta, H.B.; Mehta, V.; Girman, C.J.; Adhikari, D.; Johnson, M.L. Regression coefficient-based scoring system should be used to assign weights to the risk index. J. Clin. Epidemiol. 2016, 79, 22–28. [Google Scholar] [CrossRef] [Green Version]
- Chan, M.Y.; Sun, J.L.; Newby, L.K.; Shaw, L.K.; Lin, M.; Peterson, E.D.; Califf, R.M.; Kong, D.F.; Roe, M.T. Long-Term Mortality of Patients Undergoing Cardiac Catheterization for ST-Elevation and Non-ST-Elevation Myocardial Infarction. Circulation 2009, 119, 3110–3117. [Google Scholar] [CrossRef]
- McManus, D.D.; Gore, J.; Yarzebski, J.; Spencer, F.; Lessard, D.; Goldberg, R.J. Recent Trends in the Incidence, Treatment, and Outcomes of Patients with STEMI and NSTEMI. Am. J. Med. 2011, 124, 40–47. [Google Scholar] [CrossRef] [Green Version]
- Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Chaitman, B.R.; Bax, J.J.; Morrow, D.A.; White, H.D. The Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Circulation 2018, 138, e618–e651. [Google Scholar]
- Charlot, M.; Grove, E.L.; Hansen, T.; Olesen, J.B.; Ahlehoff, O.; Selmer, C.; Lindhardsen, J.; Madsen, J.K.; Køber, L.; Torp-Pedersen, C.; et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: Nationwide propensity score matched study. BMJ 2011, 342, d2690. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Charlot, M.; Ahlehoff, O.; Norgaard, M.L.; Jørgensen, C.H.; Sørensen, R.; Abildstrøm, S.Z.; Hansen, P.R.; Madsen, J.K.; Køber, L.; Torp-Pedersen, C.; et al. Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use. Ann. Intern. Med. 2010, 153, 378–386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goodman, S.G.; Clare, R.; Pieper, K.S.; Mahaffey, K.W.; Harrington, R.A.; Nicolau, J.C.; Storey, R.F.; Cantor, W.J.; Angiolillo, D.J.; Husted, S.; et al. Response to Letter Regarding Article, “Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes with Clopidogrel and Ticagrelor: Insights from PLATO”. Circulation 2012, 126, e171–e172. [Google Scholar] [CrossRef] [Green Version]
- Juurlink, D.N.; Dormuth, C.R.; Huang, A.; Hellings, C.; Paterson, J.M.; Raymond, C.; Kozyrskyj, A.; Moride, Y.; Macdonald, E.M.; Mamdani, M.M. Proton Pump Inhibitors and the Risk of Adverse Cardiac Events. PLoS ONE 2013, 8, e84890. [Google Scholar] [CrossRef]
- Takahama, H.; Asanuma, H.; Sanada, S.; Fujita, M.; Sasaki, H.; Wakeno, M.; Kim, J.; Asakura, M.; Takashima, S.; Minamino, T.; et al. A histamine H2 receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade. Basic Res. Cardiol. 2010, 105, 787–794. [Google Scholar] [CrossRef]
- Zeng, Z.; Shen, L.; Li, X.; Luo, T.; Wei, X.; Zhang, J.; Cao, S.; Huang, X.; Fukushima, Y.; Bin, J.; et al. Disruption of histamine H2 receptor slows heart failure progression through reducing myocardial apoptosis and fibrosis. Clin. Sci. 2014, 127, 435–448. [Google Scholar] [CrossRef]
- Kitakaze, M. Clinical Evidence of the Role of Histamine in Heart Failure. J. Am. Coll. Cardiol. 2016, 67, 1553–1555. [Google Scholar] [CrossRef]
- Leary, P.J.; Tedford, R.J.; Bluemke, D.A.; Bristow, M.R.; Heckbert, S.R.; Kawut, S.M.; Krieger, E.V.; Lima, J.A.; Masri, C.S.; Ralph, D.D.; et al. Histamine H2 Receptor Antagonists, Left Ventricular Morphology, and Heart Failure Risk: The MESA Study. J. Am. Coll. Cardiol. 2016, 67, 1544–1552. [Google Scholar] [CrossRef]
- Asanuma, H.; Minamino, T.; Ogai, A.; Kim, J.; Asakura, M.; Komamura, K.; Sanada, S.; Fujita, M.; Hirata, A.; Wakeno, M. Blockade of histamine H2 receptors protects the heart against ischemia and reperfusion injury in dogs. J. Mol. Cell. Cardiol. 2006, 40, 666–674. [Google Scholar] [CrossRef]
- Pitt, B.; Loscalzo, J.; Yčas, J.W.; Raichlen, J.S. Lipid Levels After Acute Coronary Syndromes. J. Am. Coll. Cardiol. 2008, 51, 1440–1445. [Google Scholar] [CrossRef] [Green Version]
- Rosenson, R.S. Myocardial injury: The acute phase response and lipoprotein metabolism. J. Am. Coll. Cardiol. 1993, 22, 933–940. [Google Scholar] [CrossRef] [Green Version]
- Reddy, V.S.; Bui, Q.T.; Jacobs, J.R.; Begelman, S.M.; Miller, D.P.; French, W.J.; Investigators of National Registry of Myocardial Infarction (NRMI) 4b–5. Relationship Between Serum Low-Density Lipoprotein Cholesterol and In-hospital Mortality Following Acute Myocardial Infarction (The Lipid Paradox). Am. J. Cardiol. 2015, 115, 557–562. [Google Scholar] [CrossRef] [PubMed]
- Driver, J.A.; Gaziano, J.M.; Gelber, R.P.; Lee, I.-M.; Buring, J.E.; Kurth, T. Development of a Risk Score for Colorectal Cancer in Men. Am. J. Med. 2007, 120, 257–263. [Google Scholar] [CrossRef] [PubMed]
- Vaitheeswaran, K.; Ramakrishnan, R.; Subbiah, M.; Rajiv, R. Risk score estimation of diabetic retinopathy: Statistical alternatives using multiple logistic regression. J. Biomet. Biostat. 2014, 5, 5. [Google Scholar]
- Grant, S.W.; Collins, G.S.; Nashef, S.A.M. Statistical Primer: Developing and validating a risk prediction model. Eur. J. Cardio Thorac. Surg. 2018, 54, 203–208. [Google Scholar] [CrossRef]
Composite Cardiovascular Events | ||
---|---|---|
Variable | HR (95% CI) | p |
Age; yr | 1.042 (1.023–1.060) | <0.001 |
Door-to-balloon time < 90 min; yes/no | 0.552 (0.371–0.821) | 0.003 |
WBC at admission; /mm3 | 1.000 (1.000–1.000) | <0.001 |
HDL-cholesterol at admission; mg/dL | 0.979 (0.961–0.997) | 0.023 |
Blood glucose at admission; mg/dL | 1.002 (1.000–1.004) | 0.032 |
BNP at any time; pg/dL | 1.001 (1.001–1.001) | <0.001 |
Insulin; yes/no | 2.126 (1.022–4.425) | 0.044 |
H2 blocker; yes/no | 2.000 (1.083–3.693) | 0.027 |
All-cause death | ||
Variable | HR (95% CI) | p |
Age; yr | 1.067 (1.030–1.105) | <0.001 |
Dyslipidemia; yes/no | 0.389 (0.192–0.787) | 0.009 |
Door-to-balloon time < 90 min; yes/no | 0.472 (0.238–0.937) | 0.032 |
Acute kidney injury; yes/no | 3.622 (1.684–7.790) | <0.001 |
WBC at admission; /mm3 | 1.000 (1.000–1.000) | 0.003 |
BNP at any time; pg/dL | 1.001 (1.001–1.002) | <0.001 |
H2 blocker; yes/no | 3.958 (1.634–9.584) | 0.002 |
Composite Cardiovascular Events | ||
---|---|---|
Variable | HR (95% CI) | p |
Killip class; II/I | 2.144 (0.985–4.665) | 0.055 |
Killip class; III/I | 3.944 (1.964–7.919) | <0.001 |
Killip class; IV/I | 6.826 (3.377–13.795) | <0.001 |
Dyslipidemia; yes/no | 0.553 (0.342–0.894) | 0.016 |
History of coronary artery bypass surgery; yes/no | 2.387 (1.014–5.623) | 0.047 |
2.054 (1.072–3.935) | 0.03 | |
History of stroke; yes/no | 1.000 (1.000–1.000) | 0.012 |
maxCK; IU/L | 0.990 (0.983–0.998) | <0.001 |
LDL cholesterol at admission; mg/dL | 1.604 (1.077–2.387) | 0.02 |
K at admission; mEq/L | 3.278 (1.734–6.195) | <0.001 |
All cause death | ||
Variable | HR (95% CI) | p |
Age; yr | 1.077 (1.038–1.118) | <0.001 |
VT/VF; yes/no | 4.747 (1.668–13.512) | 0.004 |
maxCK; IU/L | 1.000 (1.000–1.000) | <0.001 |
UA mg/dL | 1.323 (1.092–1.603) | 0.004 |
LDL mg/dL | 0.981 (0.969–0.994) | 0.003 |
BS mg/dL | 1.005 (1.002–1.008) | <0.001 |
Composite Cardiovascular Events | ||
---|---|---|
Variable | HR (95% CI) | p |
Intra-aortic balloon pumping | 2.408 (1.058–5.480) | 0.036 |
eGFR at admission; mL/min/1.73 m2 | 0.984 (0.974–0.995) | 0.003 |
Antiplatelet drugs; yes/no | 2.830 (1.631–4.912) | <0.001 |
Diuretics; yes/no | 2.336 (1.281–4.261) | 0.006 |
All-cause death | ||
Variable | HR (95% CI) | p |
History of coronary angioplasty; yes/no | 3.184 (1.268–7.994) | 0.014 |
Acute kidney injury; yes/no | 3.563 (1.049–12.102) | 0.042 |
RBC at admission; yes/no | 0.990 (0.983–0.998) | 0.009 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Toyoda, S.; Sakuma, M.; Abe, S.; Inoue, T.; Nakao, K.; Ozaki, Y.; Kimura, K.; Ako, J.; Noguchi, T.; Suwa, S.; et al. Prediction of Long-Term Outcomes in ST-Elevation Myocardial Infarction and Non-ST Elevation Myocardial Infarction with and without Creatinine Kinase Elevation—Post-Hoc Analysis of the J-MINUET Study. J. Clin. Med. 2020, 9, 2667. https://doi.org/10.3390/jcm9082667
Toyoda S, Sakuma M, Abe S, Inoue T, Nakao K, Ozaki Y, Kimura K, Ako J, Noguchi T, Suwa S, et al. Prediction of Long-Term Outcomes in ST-Elevation Myocardial Infarction and Non-ST Elevation Myocardial Infarction with and without Creatinine Kinase Elevation—Post-Hoc Analysis of the J-MINUET Study. Journal of Clinical Medicine. 2020; 9(8):2667. https://doi.org/10.3390/jcm9082667
Chicago/Turabian StyleToyoda, Shigeru, Masashi Sakuma, Shichiro Abe, Teruo Inoue, Koichi Nakao, Yukio Ozaki, Kazuo Kimura, Junya Ako, Teruo Noguchi, Satoru Suwa, and et al. 2020. "Prediction of Long-Term Outcomes in ST-Elevation Myocardial Infarction and Non-ST Elevation Myocardial Infarction with and without Creatinine Kinase Elevation—Post-Hoc Analysis of the J-MINUET Study" Journal of Clinical Medicine 9, no. 8: 2667. https://doi.org/10.3390/jcm9082667